Handheld Fluorescent Immunoassay Analyzer for Rapid POC Testing to Transform Clinical Diagnostics
By LabMedica International staff writers Posted on 17 Jul 2023 |
An automated, compact, and affordable fluorescent Immunoassay (FIA) solution is designed to transform the landscape of clinical point-of-care (POC) diagnostics.
Anbio Biotechnology (Frankfurt, Germany) has launched the new AF-100S FIA Solution, a compact, handheld solution for point-of-care immunodiagnostic needs that delivers rapid, accurate, and reliable results. The innovative analyzer is capable of detecting a broad spectrum of analytes, such as hormones, enzymes, and infectious diseases, making it a versatile diagnostic tool. Its compact design, lasting battery life, and user-friendly interface make it a practical choice for diverse environments. Its high sensitivity and specificity guarantee that patients are provided accurate results.
The AF-100S employs fluorescently labeled antibodies or antigens to identify specific biomolecules in a patient's sample. When a sample is combined with these labeled antibodies or antigens, the biomolecule, if present, binds to these labeled molecules, creating a complex that releases a fluorescent signal. This signal is then measured and compared with a recognized standard to ascertain the biomolecule's concentration in the sample.
This small yet efficient FIA analyzer can perform up to 240 tests per hour, making it a good fit for high-volume settings. It is powered by a lithium battery that supports up to 800 tests per charge or offers 20 days of device standby time. Its user-friendly interface, shown on a large color touchscreen, simplifies operation. The compact size of the AF-100S, measuring just 195x100x70mm, makes it an optimal choice for various medical settings such as private clinics, urgent care centers, emergency departments, and ambulances.
"The Anbio AF-100S is set to transform the field of clinical diagnostics, empowering healthcare providers with a cost-effective and comprehensive solution," said Sa Jiang, Chief Marketing Officer at Anbio. "Our FIA solution is small, yet powerful point-of-care immunodiagnostic solution that provides rapid, accurate, and reliable results for a wide range of analytes to provide faster diagnosis and better prognosis to patients."
Related Links:
Anbio Biotechnology
Latest Immunology News
- AI Predicts Tumor-Killing Cells with High Accuracy
- Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
- AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
- Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
- Testing Method Could Help More Patients Receive Right Cancer Treatment
- Groundbreaking Test Monitors Radiation Therapy Toxicity in Cancer Patients
- State-Of-The Art Techniques to Investigate Immune Response in Deadly Strep A Infections
- Novel Immunoassays Enable Early Diagnosis of Antiphospholipid Syndrome
- New Test Could Predict Immunotherapy Success for Broader Range Of Cancers
- Simple Blood Protein Tests Predict CAR T Outcomes for Lymphoma Patients
- Cell Sorter Chip Technology to Pave Way for Immune Profiling at POC
- Chip Monitors Cancer Cells in Blood Samples to Assess Treatment Effectiveness
- Automated Immunohematology Approaches Can Resolve Transplant Incompatibility
- AI Leverages Tumor Genetics to Predict Patient Response to Chemotherapy
- World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw
- Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form